This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Cancer Research Technology Limited. Active years: 2020-2024.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2024
Title: Kabir Ali Khan: Innovator in Angiogenesis Inhibition
Introduction
Kabir Ali Khan is a notable inventor based in Toronto, Canada. He has made significant contributions to the field of medical research, particularly in the area of angiogenesis inhibition. With a total of 2 patents, his work is paving the way for innovative treatments in cancer therapy.
Latest Patents
Kabir's latest patents focus on inhibitors of the interaction between CLEC14A and multimerin-2 for the inhibition of angiogenesis. The invention provides a method of inhibiting angiogenesis in an individual by administering an agent that inhibits the interaction between CLEC14A and MMRN2. The inhibitors may include various forms such as antibodies, polypeptides, peptides, polynucleotides, peptidomimetics, natural products, carbohydrates, aptamers, or small molecules.
Career Highlights
Kabir Ali Khan is currently associated with Cancer Research Technology Limited, where he continues to advance his research and innovations. His work is crucial in developing new therapeutic strategies for cancer treatment.
Collaborations
He collaborates with esteemed colleagues such as Roy Bicknell and Peter Noy, contributing to a dynamic research environment that fosters innovation and discovery.
Conclusion
Kabir Ali Khan's contributions to the field of angiogenesis inhibition highlight his role as a leading inventor in medical research. His innovative patents and collaborations are set to make a significant impact on cancer therapies in the future.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile